Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform

Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 15 months that has remained unchanged despite advances in the standard of care. GBM cells express human cytomegalovirus (HCMV) proteins, providing a unique opportunity for targeted therapy. We utilized our...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Amit S., Macauley, Juliete, Johnson, Yoshimi, Connolly, Mike, Coleman, Timothy, Heiland, Teri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149224/
https://www.ncbi.nlm.nih.gov/pubmed/35651802
http://dx.doi.org/10.3389/fonc.2022.850546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149224/
https://www.ncbi.nlm.nih.gov/pubmed/35651802
http://dx.doi.org/10.3389/fonc.2022.850546

Ejemplares similares